查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800999

2025-2033年醫院感染治療市場報告（依藥物類型、適應症及地區）

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球醫院感染治療市場規模達131億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到196億美元，2025-2033年期間的複合年成長率（CAGR）為4.32%。多重抗藥性感染發病率的不斷上升、對抗菌藥物管理的日益重視、研發的持續進步以及全球醫療支出和基礎設施建設的不斷增加，是影響市場成長的一些關鍵因素。

醫院感染治療市場趨勢：

院內感染（HAI）發生率不斷上升：

醫院感染治療市場的主要促進因素之一是醫院感染（HAI）發生率的上升。這些感染可能由細菌、病毒或真菌引起，通常與侵入性醫療操作、手術或醫療器械的使用有關。 HAI的流行是全球關注的重大問題，導致對有效療法的需求日益成長，以控制和治療這些感染。此外，抗藥性病原體在醫療機構內的蔓延進一步加劇了對先進且有針對性的治療方案的需求，因此有必要開發創新且有效的療法來有效對抗這些感染。

抗菌藥物管理計劃意識不斷增強

抗菌藥物管理計畫已成為對抗抗菌藥物抗藥性出現和蔓延的關鍵策略，並日益受到重視。這些項目致力於最佳化抗菌藥物的使用，以改善患者預後，同時最大限度地減少抗藥性的產生。抗菌藥物管理意識的不斷增強，促使人們更加重視開發和採用能夠應對抗藥性病原體所帶來具體挑戰的新型療法，這為市場擴張創造了積極的前景。此外，全球各地的各類醫療保健組織和監管機構正在積極推廣抗菌藥物管理，以確保合理使用抗生素和其他抗菌藥物，從而推動市場成長。

研發活動取得重大進展

傳染病領域持續進行的研發活動大大促進了醫院感染治療市場的擴張。同時，基因組學、微生物學和免疫學的進步為理解感染機制和識別新型藥物標靶提供了寶貴的見解。新型抗菌化合物的發現和聯合療法的開發也有助於市場擴張。此外，製藥公司、學術機構和研究組織之間的廣泛合作推動了創新治療方式的發現和開發，包括單株抗體、疫苗和新型抗生素，從而推動了市場的成長。

醫療支出增加和基礎設施發展

全球醫療支出的成長以及醫療產業基礎設施的持續發展，推動了醫院感染治療市場的成長。同時，許多政府和私人投資者正在投資擴大和現代化醫療設施，包括醫院和診所。這反過來又推動了對感染治療的需求，使醫療保健提供者能夠獲得有效的工具來管理和控制醫院感染的發生率，從而促進了市場的成長。此外，新興經濟體醫療基礎設施的擴張也為醫院感染治療開闢了新的市場。隨著醫療服務可近性的改善，對先進治療方案的需求激增，以應對與傳染病相關的醫療挑戰。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球醫院感染治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥物類型

  • 抗菌藥物
  • 抗真菌藥物
  • 抗病毒藥物
  • 其他

第7章：市場區隔：依指標

  • 血流感染
  • 泌尿道感染
  • 手術部位感染
  • 肺炎
  • 其他

第8章：市場區隔：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章：SWOT分析

第 10 章：價值鏈分析

第 11 章：波特五力分析

第 12 章：價格分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Allergan Plc (AbbVie Inc.)
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A2393

The global hospital infection therapeutics market size reached USD 13.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.32% during 2025-2033. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

Breakup by Drug Type:

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Anti-bacterial drugs accounts for the majority of the market share

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

  • Blood Stream Infections
  • Urinary Tract Infections
  • Surgical Site Infections
  • Pneumonia
  • Others

Surgical site infections holds the largest share of the industry

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allergan Plc (AbbVie Inc.)
  • AstraZeneca Plc
  • Bayer Aktiengesellschaft
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Pfizer Inc.
  • Sanofi S.A.

Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive hospital infection therapeutics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the hospital infection therapeutics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the hospital infection therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hospital infection therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players